Molecular Partners (NASDAQ:MOLN – Get Free Report) and Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.
Insider and Institutional Ownership
26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are held by institutional investors. 5.9% of Molecular Partners shares are held by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Molecular Partners and Cartesian Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Molecular Partners | $5.65 million | 22.03 | -$74.41 million | ($1.68) | -1.84 |
| Cartesian Therapeutics | $2.00 million | 107.63 | -$130.30 million | ($4.94) | -1.44 |
Molecular Partners has higher revenue and earnings than Cartesian Therapeutics. Molecular Partners is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Molecular Partners and Cartesian Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Molecular Partners | N/A | -80.03% | -62.56% |
| Cartesian Therapeutics | -8,550.65% | N/A | -23.63% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Molecular Partners and Cartesian Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Molecular Partners | 1 | 1 | 2 | 0 | 2.25 |
| Cartesian Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
Molecular Partners currently has a consensus price target of $8.38, suggesting a potential upside of 171.65%. Cartesian Therapeutics has a consensus price target of $32.60, suggesting a potential upside of 358.90%. Given Cartesian Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than Molecular Partners.
Volatility & Risk
Molecular Partners has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.
Summary
Cartesian Therapeutics beats Molecular Partners on 9 of the 14 factors compared between the two stocks.
About Molecular Partners
Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland. The company develops therapeutic molecules based on its proprietary DARPin platform, which uses designed ankyrin repeat proteins to create targeted, multi-specific medicines intended to address complex disease pathways. Molecular Partners’ research and development activities have focused primarily on oncology, ophthalmology and infectious diseases. Its pipeline has included experimental programs designed to engage multiple biological targets, with the goal of improving treatment effectiveness and addressing limitations associated with conventional antibody-based therapies.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s platform is designed to program a patient’s own immune cells with messenger RNA, enabling the development of cell therapies that are intended to provide targeted treatment without permanent genetic modification. Cartesian’s lead product candidate is Descartes-08, an autologous CAR T-cell therapy that targets B-cell maturation antigen (BCMA).
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
